Skip to main content
MedWatcherBeta

Loading research and source information…

An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients With Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study for Crohn’s disease: evidence and status · MedWatcher